Literature DB >> 33731668

p97/VCP is highly expressed in the stem-like cells of breast cancer and controls cancer stemness partly through the unfolded protein response.

Chuang Li1,2, Yongsheng Huang3,4, Qianqian Fan1,5, Hongyang Quan1,6, Yeqing Dong7, Meng Nie1,8, Jiaqi Wang9, Fucun Xie9, Jiang Ji9, Lan Zhou1,10, Zhi Zheng7, Lin Wang11.   

Abstract

p97/VCP, an evolutionarily concerned ATPase, partakes in multiple cellular proteostatic processes, including the endoplasmic reticulum (ER)-associated protein degradation (ERAD). Elevated expression of p97 is common in many cancers and is often associated with poor survival. Here we report that the levels of p97 positively correlated with the histological grade, tumor size, and lymph node metastasis in breast cancers. We further examined p97 expression in the stem-like cancer cells or cancer stem cells (CSCs), a cell population that purportedly underscores cancer initiation, therapeutic resistance, and recurrence. We found that p97 was consistently at a higher level in the CD44+/CD24-, ALDH+, or PKH26+ CSC populations than the respective non-CSC populations in human breast cancer tissues and cancer cell lines and p97 expression also positively correlated with that of SOX2, another CSC marker. To assess the role of p97 in breast cancers, cancer proliferation, mammosphere, and orthotopic growth were analyzed. Similarly as p97 depletion, two pharmacological inhibitors, which targets the ER-associated p97 or globally inhibits p97's ATPase activity, markedly reduced cancer growth and the CSC population. Importantly, depletion or inhibition of p97 greatly suppressed the proliferation of the ALDH+ CSCs and the CSC-enriched mammospheres, while exhibiting much less or insignificant inhibitory effects on the non-CSC cancer cells. Comparable phenotypes produced by blocking ERAD suggest that ER proteostasis is essential for the CSC integrity. Loss of p97 gravely activated the unfolded protein response (UPR) and modulated the expression of multiple stemness and pluripotency regulators, including C/EBPδ, c-MYC, SOX2, and SKP2, which collectively contributed to the demise of CSCs. In summary, p97 controls the breast CSC integrity through multiple targets, many of which directly affect cancer stemness and are induced by UPR activation. Our findings highlight the importance of p97 and ER proteostasis in CSC biology and anticancer therapy.

Entities:  

Year:  2021        PMID: 33731668      PMCID: PMC7969628          DOI: 10.1038/s41419-021-03555-5

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  50 in total

1.  p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.

Authors:  Thang Van Nguyen; Jing Li; Chin-Chun Jean Lu; Jennifer L Mamrosh; Gang Lu; Brian E Cathers; Raymond J Deshaies
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

2.  Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.

Authors:  Tsui-Fen Chou; Steve J Brown; Dmitriy Minond; Brian E Nordin; Kelin Li; Amanda C Jones; Peter Chase; Patrick R Porubsky; Brian M Stoltz; Frank J Schoenen; Matthew P Patricelli; Peter Hodder; Hugh Rosen; Raymond J Deshaies
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

Review 3.  Breast cancer molecular subtypes: from TNBC to QNBC.

Authors:  Jane Date C Hon; Baljit Singh; Aysegul Sahin; Gang Du; Jinhua Wang; Vincent Y Wang; Fang-Ming Deng; David Y Zhang; Marie E Monaco; Peng Lee
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

4.  Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.

Authors:  Junling Si; Xueyan Yu; Yingjie Zhang; James W DeWille
Journal:  Mol Cancer       Date:  2010-04-28       Impact factor: 27.401

5.  The three branches of the unfolded protein response exhibit differential significance in breast cancer growth and stemness.

Authors:  Chuang Li; Qianqian Fan; Hongyang Quan; Meng Nie; Yunping Luo; Lin Wang
Journal:  Exp Cell Res       Date:  2018-03-27       Impact factor: 3.905

6.  Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.

Authors:  D Ruan; J He; C-F Li; H-J Lee; J Liu; H-K Lin; C-H Chan
Journal:  Oncogene       Date:  2017-03-27       Impact factor: 9.867

7.  The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation.

Authors:  Katarzyna Parzych; Paula Saavedra-García; Gabriel N Valbuena; Hibah A Al-Sadah; Mark E Robinson; Lucy Penfold; Desislava M Kuzeva; Angie Ruiz-Tellez; Sandra Loaiza; Viktoria Holzmann; Valentina Caputo; David C Johnson; Martin F Kaiser; Anastasios Karadimitris; Eric W-F Lam; Eric Chevet; Niklas Feldhahn; Hector C Keun; Holger W Auner
Journal:  Oncogene       Date:  2019-01-09       Impact factor: 9.867

Review 8.  Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis.

Authors:  Matthew Ho Zhi Guang; Emma L Kavanagh; Luke Paul Dunne; Paul Dowling; Li Zhang; Sinéad Lindsay; Despina Bazou; Chia Yin Goh; Cathal Hanley; Giada Bianchi; Kenneth C Anderson; Peter O'Gorman; Amanda McCann
Journal:  Cancers (Basel)       Date:  2019-01-09       Impact factor: 6.639

Review 9.  Chaperones and Beyond as Key Players in Pluripotency Maintenance.

Authors:  Camila Felix de Lima Fernandes; Rebeca Piatniczka Iglesia; Maria Isabel Melo-Escobar; Mariana Brandão Prado; Marilene Hohmuth Lopes
Journal:  Front Cell Dev Biol       Date:  2019-08-02

10.  Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts.

Authors:  Suling Liu; Yang Cong; Dong Wang; Yu Sun; Lu Deng; Yajing Liu; Rachel Martin-Trevino; Li Shang; Sean P McDermott; Melissa D Landis; Suhyung Hong; April Adams; Rosemarie D'Angelo; Christophe Ginestier; Emmanuelle Charafe-Jauffret; Shawn G Clouthier; Daniel Birnbaum; Stephen T Wong; Ming Zhan; Jenny C Chang; Max S Wicha
Journal:  Stem Cell Reports       Date:  2013-12-27       Impact factor: 7.765

View more
  6 in total

1.  Multiple UBX proteins reduce the ubiquitin threshold of the mammalian p97-UFD1-NPL4 unfoldase.

Authors:  Ryo Fujisawa; Cristian Polo Rivera; Karim P M Labib
Journal:  Elife       Date:  2022-08-03       Impact factor: 8.713

2.  NMS-873 Leads to Dysfunctional Glycometabolism in A p97-Independent Manner in HCT116 Colon Cancer Cells.

Authors:  Shan Li; Feng Wang; Gang Zhang; Tsui-Fen Chou
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

3.  An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer.

Authors:  Susan Costantini; Andrea Polo; Francesca Capone; Marina Accardo; Angela Sorice; Rita Lombardi; Palmina Bagnara; Federica Zito Marino; Martina Amato; Michele Orditura; Maddalena Fratelli; Gennaro Ciliberto; Alfredo Budillon
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

4.  Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.

Authors:  Ke Zhu; Liu Xiaoqiang; Wen Deng; Gongxian Wang; Bin Fu
Journal:  Hum Genomics       Date:  2021-12-20       Impact factor: 4.639

5.  Proteomics-based identification of the role of osteosarcoma amplified-9 in hepatocellular carcinoma recurrence.

Authors:  Xuyong Wei; Mengfan Yang; Binhua Pan; Xiaobing Zhang; Hanchao Lin; Wangyao Li; Wenzhi Shu; Kun Wang; Abdul Rehman Khan; Xuanyu Zhang; Beini Cen; Xiao Xu
Journal:  Hepatol Commun       Date:  2022-04-16

6.  PERK signaling through C/EBPδ contributes to ER stress-induced expression of immunomodulatory and tumor promoting chemokines by cancer cells.

Authors:  Namratha Sheshadri; Dipak K Poria; Shikha Sharan; Ying Hu; Chunhua Yan; Vishal N Koparde; Kuppusamy Balamurugan; Esta Sterneck
Journal:  Cell Death Dis       Date:  2021-11-01       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.